CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
IV Zometadrug
Likely dose
IV Zometa 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00301873
NCT00301873Phase 2Completed
CompareCT.gov

Phase II Study of Zometa (Zoledronic Acid) to Prevent Osteoporosis in Patients With Brain Tumors

Duke University·interventional·Posted Mar 13, 2006·Updated Feb 18, 2013

In Brief

A Phase 2 clinical trial evaluating IV Zometa for Brain Tumors and 2 related conditions. Completed, enrolled 60 participants across 1 site.

Detailed Summary

RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
CountriesUnited States
CollaboratorsNovartis, National Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 13, 2006
Enrollment StartMay 1, 2006
Primary CompletionFeb 1, 2011
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 20.3 years ago

Interventions

IV Zometadrug

Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.